UPDATE: H.C. Wainwright Maintains Buy On Karyopharm Therapeutics, Raises Target To $36 Notes 'Xpovio Launch Starts Strong'; 'Topline BOSTON data expected early 2020', 'NDA submission is expected in 2020 if the BOSTON data are positive'
Benzinga_Newsdesk